Tariff Update: New Section 232 Tariffs Take Effect for…
U.S. Customs and Border Protection has implemented new Section 232 tariffs of up to 100% on specific patented pharmaceutical products and ingredients. The measures, which began in July 2026, exclude generic drugs and investigational products used in clinical research.
Why it matters
These tariffs significantly impact the supply chain and cost structure for pharmaceutical companies importing patented goods into the U.S.
AUTHOR: Reynaldo Roman - Senior Director, Regulatory Compliance
On July 31, 2026, U.S. Customs and Border Protection (CBP) issued guidance implementing new Section 232 tariffs on certain patented pharmaceutical products and related pharmaceutical ingredients imported into the United States. The guidance outlines the products covered, applicable tariff rates, reporting requirements, and available exceptions established under Presidential Proclamation 11020.
The new tariffs took effect in phases beginning July 31, 2026, with added tariff provisions scheduled to take effect on September 29, 2026, depending on the manufacturer. For covered products, the new Section 232 tariffs can be as high as 100% , making it important for importers to determine whether their products fall within the scope of the new requirements. The guidance also establishes new Chapter 99 reporting requirements for covered entries.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in